300122 智飞生物
已收盘 05-22 15:00:00
资讯
新帖
简况
智飞生物：司美格鲁肽注射液（超重/肥胖）正处于Ⅲ期临床试验阶段
证券之星 · 05-22 17:06
智飞生物：司美格鲁肽注射液（超重/肥胖）正处于Ⅲ期临床试验阶段
智飞生物：人二倍体狂犬病疫苗等五款核心产品已提交上市申请
证券之星 · 05-22 17:00
智飞生物：人二倍体狂犬病疫苗等五款核心产品已提交上市申请
智飞生物：持续加快产品创新，推动在研管线进展
证券之星 · 05-22 16:57
智飞生物：持续加快产品创新，推动在研管线进展
股市必读：智飞生物（300122）5月15日董秘有最新回复
证券之星 · 05-18
股市必读：智飞生物（300122）5月15日董秘有最新回复
智飞生物：公司持续加快产品创新，推动在研管线进展
证券之星 · 05-15
智飞生物：公司持续加快产品创新，推动在研管线进展
智飞生物及董事长蒋仁生收监管函 多期财报数据不准确
中金财经 · 05-11
智飞生物及董事长蒋仁生收监管函 多期财报数据不准确
股市必读：智飞生物（300122）5月8日董秘有最新回复
证券之星 · 05-11
股市必读：智飞生物（300122）5月8日董秘有最新回复
投资“100万只剩几万块”！智飞生物业绩会上遭吐槽，公司去年巨亏147亿，年报开篇向投资人致歉
澎湃新闻 · 05-10
投资“100万只剩几万块”！智飞生物业绩会上遭吐槽，公司去年巨亏147亿，年报开篇向投资人致歉
智飞生物：截至2026年4月30日，公司普通股股东人数为119,480
证券之星 · 05-09
智飞生物：截至2026年4月30日，公司普通股股东人数为119,480
智飞生物：2025年度，公司管理层自愿放弃部分2025年度薪酬，总薪酬同比下降
证券之星 · 05-09
智飞生物：2025年度，公司管理层自愿放弃部分2025年度薪酬，总薪酬同比下降
每周股票复盘：智飞生物（300122）一季度净亏损3.88亿元
证券之星 · 05-03
每周股票复盘：智飞生物（300122）一季度净亏损3.88亿元
智飞生物：2025年董事高管薪酬较2024年平均降幅20.8％
证券之星 · 04-30
智飞生物：2025年董事高管薪酬较2024年平均降幅20.8％
智飞生物：关于公司申请银团贷款暨子公司及公司关联方提供担保的公告
证券之星 · 04-30
智飞生物：关于公司申请银团贷款暨子公司及公司关联方提供担保的公告
智飞生物营收连降 首季亏3.88亿元去年亏147.23亿元
中金财经 · 04-29
智飞生物营收连降 首季亏3.88亿元去年亏147.23亿元
股市必读：智飞生物（300122）4月17日董秘有最新回复
证券之星 · 04-20
股市必读：智飞生物（300122）4月17日董秘有最新回复
智飞生物：公司于2025年以增资形式实现对宸安生物控股
证券之星 · 04-17
智飞生物：公司于2025年以增资形式实现对宸安生物控股
智飞生物取消千亿刚性采购背后：HPV疫苗市场逆转，业绩断崖式巨亏
证券之星 · 04-14
智飞生物取消千亿刚性采购背后：HPV疫苗市场逆转，业绩断崖式巨亏
智飞生物与默沙东调整合作协议：取消千亿保底采购，转向弹性模式
中国经营报 · 04-07
智飞生物与默沙东调整合作协议：取消千亿保底采购，转向弹性模式
智飞生物（300122）披露与默沙东调整战略合作协议，4月3日股价下跌2.23%
证券之星 · 04-03
智飞生物（300122）披露与默沙东调整战略合作协议，4月3日股价下跌2.23%
智飞生物修订与默沙东协议 “五连板”津药药业称无在研创新药
财闻 · 04-02
智飞生物修订与默沙东协议 “五连板”津药药业称无在研创新药
加载更多
公司概况
公司名称：
重庆智飞生物制品股份有限公司
所属行业：
医药制造业
上市日期：
2010-09-28
主营业务：
重庆智飞生物制品股份有限公司的主营业务是疫苗、生物制品研发、生产、销售、推广、配送及进出口。公司的主要产品是盟威克、盟纳康、喜菲贝、盟纳克、智克威得、宜卡、微卡、优威克、四价流感病毒裂解疫苗、佳达修、佳达修9、乐儿德、纽莫法、维康特、欣安立适。
发行价格：
37.98
{"stockData":{"symbol":"300122","market":"SZ","secType":"STK","nameCN":"智飞生物","latestPrice":14.06,"timestamp":1779433419000,"preClose":14.49,"halted":0,"volume":22605476,"delay":0,"changeRate":-0.0297,"floatShares":1414000000,"shares":2394000000,"eps":-6.1778,"marketStatus":"已收盘","change":-0.43,"latestTime":"05-22 15:00:00","open":14.49,"high":14.55,"low":14,"amount":320000000,"amplitude":0.038,"askPrice":14.07,"askSize":365,"bidPrice":14.06,"bidSize":1531,"shortable":0,"etf":0,"ttmEps":-6.1778,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1779672600000},"marketStatusCode":5,"adr":0,"adjPreClose":14.49,"symbolType":"stock","openAndCloseTimeList":[[1779413400000,1779420600000],[1779426000000,1779433200000]],"highLimit":15.94,"lowLimit":13.04,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":2393789747,"isCdr":false,"pbRate":2.24,"roa":"--","roe":"--","epsLYR":-6.1506,"committee":0.738681,"marketValue":33657000000,"turnoverRate":0.016,"status":1,"floatMarketCap":19885000000},"requestUrl":"/m/hq/s/300122","defaultTab":"news","newsList":[{"id":"2637397349","title":"智飞生物：司美格鲁肽注射液（超重/肥胖）正处于Ⅲ期临床试验阶段","url":"https://stock-news.laohu8.com/highlight/detail?id=2637397349","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2637397349?lang=zh_cn&edition=full","pubTime":"2026-05-22 17:06","pubTimestamp":1779440777,"startTime":"0","endTime":"0","summary":"证券之星消息，智飞生物(300122)05月22日在投资者关系平台上答复投资者关心的问题。投资者提问：请问董秘，公司减肥产品还有多久才能上市？智飞生物回复：您好，公司司美格鲁肽注射液（超重/肥胖）正处于Ⅲ期临床试验阶段，CA111注射液正处于I期临床试验阶段。相关产品的研发进展请您持续关注公司的信息披露，谢谢！以上内容为证券之星据公开信息整理，不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026052200031099.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU1328615791.USD","LU2148510915.USD","300122","LU1064131003.USD","LU2580892862.HKD","BK0077","BK0188","BK0196","LU1064130708.USD","BK0046","LU2580892789.USD","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637939786","title":"智飞生物：人二倍体狂犬病疫苗等五款核心产品已提交上市申请","url":"https://stock-news.laohu8.com/highlight/detail?id=2637939786","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2637939786?lang=zh_cn&edition=full","pubTime":"2026-05-22 17:00","pubTimestamp":1779440427,"startTime":"0","endTime":"0","summary":"证券之星消息，智飞生物(300122)05月22日在投资者关系平台上答复投资者关心的问题。投资者提问：请问董秘，高层口口声声说大力研发新产品，公司市值都快跌没了，等新产品三年五载出来，市场还会给公司机会吗？你们为什么不快速并购更多公司，增加提升公司价值呢？市场还会给公司时间吗？智飞生物回复：您好，公司目前有五款核心产品已提交上市申请，分别是人二倍体狂犬病疫苗、15价肺炎结合疫苗、四价流脑结合疫苗、利拉鲁肽注射液、德谷胰岛素注射液。公司产品的研发进展请您持续关注公司的信息披露，谢谢！以上内容为证券之星据公开信息整理，不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026052200030771.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["159646","LU1064131003.USD","LU2580892789.USD","BK0196","BK0239","LU2580892862.HKD","BK0188","LU1064130708.USD","BK0077","300122","LU1328615791.USD","LU2148510915.USD","BK0046"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637428392","title":"智飞生物：持续加快产品创新，推动在研管线进展","url":"https://stock-news.laohu8.com/highlight/detail?id=2637428392","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2637428392?lang=zh_cn&edition=full","pubTime":"2026-05-22 16:57","pubTimestamp":1779440235,"startTime":"0","endTime":"0","summary":"证券之星消息，智飞生物(300122)05月22日在投资者关系平台上答复投资者关心的问题。投资者提问：请问董秘，创业板指已经创下十几年以来的新高，贵司股价还在不断下跌，公司还有什么实质性的利好，来提升股价，维护投资者信心？？智飞生物回复：您好，公司持续加快产品创新，推动在研管线进展；强化商业推广，优化市场策略；提升治理水平，夯实发展根基，逐步推动公司经营企稳向好，谢谢！以上内容为证券之星据公开信息整理，不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026052200030654.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0046","BK0077","LU2148510915.USD","LU1328615791.USD","BK0239","LU1064131003.USD","LU2580892862.HKD","LU2580892789.USD","300122","LU1064130708.USD","BK0196","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636101395","title":"股市必读：智飞生物（300122）5月15日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2636101395","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2636101395?lang=zh_cn&edition=full","pubTime":"2026-05-18 01:48","pubTimestamp":1779040095,"startTime":"0","endTime":"0","summary":"截至2026年5月15日收盘，智飞生物报收于15.04元，下跌0.33%，换手率1.31%，成交量18.54万手，成交额2.79亿元。董秘最新回复投资者： 请问董秘，总裁质押3亿股份资金，是对智飞进行增持，还是收购其他公司？当日关注点来自交易信息汇总：5月15日主力资金净流出2763.43万元，散户资金净流入2773.95万元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051800000769.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU1064131003.USD","LU2580892789.USD","BK0196","BK0239","LU2580892862.HKD","BK0188","LU1064130708.USD","BK0077","300122","LU1328615791.USD","LU2148510915.USD","BK0046"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635023267","title":"智飞生物：公司持续加快产品创新，推动在研管线进展","url":"https://stock-news.laohu8.com/highlight/detail?id=2635023267","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2635023267?lang=zh_cn&edition=full","pubTime":"2026-05-15 16:45","pubTimestamp":1778834722,"startTime":"0","endTime":"0","summary":"证券之星消息，智飞生物(300122)05月15日在投资者关系平台上答复投资者关心的问题。投资者提问：根据相关财经媒体的报道，公司去年亏损147亿元，居创业板第一。而与亏损相对应的是，公司股价连续下跌了6年，持有公司股票的投资者普遍亏损超50%。请问：公司有无具体扭亏为盈的措施，让股价止跌回稳呢？！智飞生物回复：您好，公司持续加快产品创新，推动在研管线进展；强化商业推广，优化市场策略；提升治理水平，夯实发展根基，逐步推动公司经营企稳向好，谢谢！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051500029431.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","LU2580892789.USD","BK0046","BK0077","LU2580892862.HKD","BK0188","LU1064131003.USD","BK0196","LU1064130708.USD","LU2148510915.USD","LU1328615791.USD","300122"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634447019","title":"智飞生物及董事长蒋仁生收监管函 多期财报数据不准确","url":"https://stock-news.laohu8.com/highlight/detail?id=2634447019","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2634447019?lang=zh_cn&edition=full","pubTime":"2026-05-11 14:29","pubTimestamp":1778480948,"startTime":"0","endTime":"0","summary":"中国经济网北京5月11日讯 深交所网站5月8日发布关于对重庆智飞生物制品股份有限公司及相关当事人的监管函 。 2026年4月28日，智飞生物披露《关于前期会计差错涉及追溯调整与年度报告更正的公告》，对2020年度至2025年第三季度会计期间涉及的部分财务报表及附注数据进行会计差错更正并追溯调整，具体调整事项涉及服务费收入确认不准确、未考虑期后退货对相关年度报表的影响以及调整现金流量表补充资料相关科目。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushijujiao/20260511/32214760.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["300122"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634426895","title":"股市必读：智飞生物（300122）5月8日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2634426895","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2634426895?lang=zh_cn&edition=full","pubTime":"2026-05-11 02:41","pubTimestamp":1778438470,"startTime":"0","endTime":"0","summary":"截至2026年5月8日收盘，智飞生物报收于15.47元，上涨0.59%，换手率1.6%，成交量22.62万手，成交额3.52亿元。2025年度，公司管理层自愿放弃部分2025年度薪酬，总薪酬同比下降。董秘： 您好，2025年度，公司业绩显著承压，公司深刻总结经验教训，着力化解各项经营风险。谢谢董秘： 您好，截至2026年4月30日，公司普通股股东人数为119,480，谢谢！","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051100001275.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU2580892862.HKD","LU1328615791.USD","LU2148510915.USD","BK0077","LU1064130708.USD","LU2580892789.USD","BK0046","300122","LU1064131003.USD","BK0188","BK0239","BK0196"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634460934","title":"投资“100万只剩几万块”！智飞生物业绩会上遭吐槽，公司去年巨亏147亿，年报开篇向投资人致歉","url":"https://stock-news.laohu8.com/highlight/detail?id=2634460934","media":"澎湃新闻","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2634460934?lang=zh_cn&edition=full","pubTime":"2026-05-10 12:02","pubTimestamp":1778385720,"startTime":"0","endTime":"0","summary":"智飞生物业绩会上遭吐槽，公司去年巨亏147亿，年报开篇向投资人致歉；重庆首富身家缩水1000亿，高管主动降薪。 对此，公司董事长蒋仁生回应称，对股东的心情深表理解，受行业深度调整等因素影响，公司当前股价持续承压。公司将通过多项举措全力化解风险，同时持续加快产品创新等，逐步推动公司经营企稳向好。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/roll/2026-05-10/doc-inhxktni2914619.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/roll/2026-05-10/doc-inhxktni2914619.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0046","BK0239","LU1064131003.USD","LU1064130708.USD","LU1328615791.USD","LU2580892789.USD","LU2580892862.HKD","BK0196","300122","LU2148510915.USD","BK0077","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634497463","title":"智飞生物：截至2026年4月30日，公司普通股股东人数为119,480","url":"https://stock-news.laohu8.com/highlight/detail?id=2634497463","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2634497463?lang=zh_cn&edition=full","pubTime":"2026-05-09 16:24","pubTimestamp":1778315047,"startTime":"0","endTime":"0","summary":"证券之星消息，智飞生物(300122)05月09日在投资者关系平台上答复投资者关心的问题。投资者提问：请问截至2026年4月30日公司的股东总数是多少？谢谢智飞生物回复：您好，截至2026年4月30日，公司普通股股东人数为119,480，谢谢！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026050900009894.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0046","BK0239","LU2580892862.HKD","BK0077","LU1064130708.USD","LU1064131003.USD","LU2148510915.USD","BK0188","300122","BK0196","LU1328615791.USD","LU2580892789.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634122497","title":"智飞生物：2025年度，公司管理层自愿放弃部分2025年度薪酬，总薪酬同比下降","url":"https://stock-news.laohu8.com/highlight/detail?id=2634122497","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2634122497?lang=zh_cn&edition=full","pubTime":"2026-05-09 16:21","pubTimestamp":1778314868,"startTime":"0","endTime":"0","summary":"证券之星消息，智飞生物(300122)05月09日在投资者关系平台上答复投资者关心的问题。投资者提问：2025年，公司高管薪酬总额增长率远超业绩增长率，请问公司的薪酬制度合理吗，是否损害了中小股东利益？智飞生物回复：您好，公司根据《公司法》《上市公司治理准则》等法律法规制定内部薪酬管理制度并严格执行。2025年度，公司管理层自愿放弃部分2025年度薪酬，总薪酬同比下降。谢谢！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026050900009745.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0077","BK0046","BK0188","LU2580892862.HKD","BK0239","LU1328615791.USD","BK0196","LU2148510915.USD","LU2580892789.USD","LU1064130708.USD","LU1064131003.USD","300122"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632672849","title":"每周股票复盘：智飞生物（300122）一季度净亏损3.88亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2632672849","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2632672849?lang=zh_cn&edition=full","pubTime":"2026-05-03 03:55","pubTimestamp":1777751711,"startTime":"0","endTime":"0","summary":"截至2026年4月30日收盘，智飞生物报收于15.15元，较上周的14.8元上涨2.36%。本周，智飞生物4月28日盘中最高价报15.49元。本周关注点业绩披露要点：智飞生物2026年一季报显示归母净利润-3.88亿元，同比下降18.79%。股本股东变化股东户数变动截至2026年4月10日，智飞生物股东户数为12.17万户，较3月31日增加163.0户，增幅0.13%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026050300000809.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","LU1328615791.USD","BK0188","BK0196","300122","LU1064131003.USD","LU2580892789.USD","LU2580892862.HKD","LU2148510915.USD","BK0046","BK0077","LU1064130708.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631680914","title":"智飞生物：2025年董事高管薪酬较2024年平均降幅20.8％","url":"https://stock-news.laohu8.com/highlight/detail?id=2631680914","media":"证券之星","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2631680914?lang=zh_cn&edition=full","pubTime":"2026-04-30 18:24","pubTimestamp":1777544645,"startTime":"0","endTime":"0","summary":"证券之星消息，智飞生物04月30日在投资者关系平台上答复投资者关心的问题。投资者提问：请问董秘，贵司股价6年超跌95%，市值蒸发几千亿，决策层出现重大失误，造成投资者重大亏损！2025年度，除去2024年新任董事、高级管理人员，其他董事、高级管理人员2025年实际薪酬较2024年平均降幅20.8％。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026043000059043.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU2580892862.HKD","LU2580892789.USD","LU1328615791.USD","LU1064130708.USD","BK0196","300122","LU1064131003.USD","BK0046","BK0239","BK0188","LU2148510915.USD","BK0077"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631300680","title":"智飞生物：关于公司申请银团贷款暨子公司及公司关联方提供担保的公告","url":"https://stock-news.laohu8.com/highlight/detail?id=2631300680","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2631300680?lang=zh_cn&edition=full","pubTime":"2026-04-30 18:21","pubTimestamp":1777544476,"startTime":"0","endTime":"0","summary":"证券之星消息，智飞生物04月30日在投资者关系平台上答复投资者关心的问题。针对以上4点问题，请详细回答，如果继续敷衍，本人会继续提问，或者通过其他媒体渠道相继报道采访贵公司，毕竟巨额损失都承受了，不在乎其他渠道来维权智飞生物回复：您好，公司于2026年1月5日披露了《关于公司申请银团贷款暨子公司及公司关联方提供担保的公告》。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026043000058983.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU2580892789.USD","LU1064130708.USD","LU2148510915.USD","BK0077","LU1064131003.USD","BK0046","BK0239","300122","LU1328615791.USD","BK0188","BK0196","LU2580892862.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631561601","title":"智飞生物营收连降 首季亏3.88亿元去年亏147.23亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2631561601","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2631561601?lang=zh_cn&edition=full","pubTime":"2026-04-29 14:57","pubTimestamp":1777445822,"startTime":"0","endTime":"0","summary":"中国经济网北京4月29日讯 智飞生物 2025年年度报告显示，公司去年实现营业收入89.58亿元，同比下降65.61%，2024年营收为260.49亿元，2023年为529.18亿元；归属于上市公司股东的净利润为-147.23亿元，上年同期为19.72亿元；归属于上市公司股东的扣除非经常性损益的净利润-147.44亿元，上年同期为19.63亿元；经营活动产生的现金流量净额为51.67亿元，上年同期为-42.24亿元。 公司2025年计提各项资产减值损失金额合计为141.28亿元。","market":"us","thumbnail":" http://caiji.3g.cnfol.com/colect/202604/29/20260429803646.png","type":0,"news_type":0,"thumbnails":[" http://caiji.3g.cnfol.com/colect/202604/29/20260429803646.png"],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushijujiao/20260429/32188537.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["300122"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628798460","title":"股市必读：智飞生物（300122）4月17日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2628798460","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2628798460?lang=zh_cn&edition=full","pubTime":"2026-04-20 01:42","pubTimestamp":1776620532,"startTime":"0","endTime":"0","summary":"截至2026年4月17日收盘，智飞生物报收于15.47元，下跌1.4%，换手率0.88%，成交量12.47万手，成交额1.94亿元。董秘： 您好，截至2026年4月10日，公司普通股股东人数为121,712，谢谢！","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042000000827.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU2580892862.HKD","LU1328615791.USD","BK0046","LU2580892789.USD","LU1064130708.USD","BK0188","300122","BK0196","BK0077","LU1064131003.USD","LU2148510915.USD","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628279290","title":"智飞生物：公司于2025年以增资形式实现对宸安生物控股","url":"https://stock-news.laohu8.com/highlight/detail?id=2628279290","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2628279290?lang=zh_cn&edition=full","pubTime":"2026-04-17 16:33","pubTimestamp":1776414801,"startTime":"0","endTime":"0","summary":"证券之星消息，智飞生物(300122)04月17日在投资者关系平台上答复投资者关心的问题。投资者提问：懂秘你好，创业板重组新规对生物医药企业并购重组有政策支持，请问公司是否会借助新规机遇，推进产业链相关的并购或资源整合工作！另外市场关注到实控人旗下的智睿投资有多个优质生物医药孵化项目，请问相关成熟项目是否有注入上市公司的计划？目前是否有具体的时间规划或审核进展！智飞生物回复：您好，公司于2025年以增资形式实现对宸安生物控股，公司业务从疫苗延伸至代谢类疾病领域。感谢关注！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026041700030875.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","LU2148510915.USD","BK0077","LU2580892789.USD","BK0239","LU1064131003.USD","300122","LU2580892862.HKD","LU1328615791.USD","BK0196","LU1064130708.USD","BK0046"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627841542","title":"智飞生物取消千亿刚性采购背后：HPV疫苗市场逆转，业绩断崖式巨亏","url":"https://stock-news.laohu8.com/highlight/detail?id=2627841542","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2627841542?lang=zh_cn&edition=full","pubTime":"2026-04-14 15:54","pubTimestamp":1776153281,"startTime":"0","endTime":"0","summary":"2017年，智飞生物成功代理并推广默沙东四价HPV疫苗，迅速打开中国市场；2018年又拿下九价HPV疫苗代理权，业绩快速增长。智飞生物解释称，受民众接种意愿下降、疫苗犹豫加剧等因素影响，疫苗行业进入深度调整。然而，取消刚性保底采购并不意味着警报解除。智飞生物后续的库存消化能力、国产九价HPV疫苗的替代效应，以及国家免疫规划落地后自费市场面临的结构性重塑，是决定公司未来走势的关键变量。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/SS2026041400023390.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0046","BK0239","LU2580892862.HKD","BK0077","LU1064130708.USD","LU2580892789.USD","LU1064131003.USD","LU2148510915.USD","BK0188","300122","BK0196","LU1328615791.USD","159646"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625959109","title":"智飞生物与默沙东调整合作协议：取消千亿保底采购，转向弹性模式","url":"https://stock-news.laohu8.com/highlight/detail?id=2625959109","media":"中国经营报","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2625959109?lang=zh_cn&edition=full","pubTime":"2026-04-07 22:19","pubTimestamp":1775571594,"startTime":"0","endTime":"0","summary":"日前，智飞生物（300122.SZ）发布公告称，公司与美国默沙东药厂有限公司签署《经修订和重述的供应、经销与共同推广协议》，对双方于2023年1月21日签署的原协议进行全面修订并予以重述，新协议自签署之日起生效，原协议同步终止。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202604073696779216.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU1066051811.HKD","SG9999001440.SGD","LU0208291251.USD","MRK","BK0188","IE00BLSP4239.USD","LU0965509101.SGD","IE00B2B36J28.USD","IE00BFTCPJ56.SGD","LU0058720904.USD","LU2360032135.SGD","LU1093756325.SGD","BK4585","BK4588","IE00B4R5TH58.HKD","LU1430594728.SGD","IE00BN8TJ469.HKD","LU1037948897.HKD","SG9999002232.USD","LU0130102774.USD","LU0868494708.USD","LU1989772840.SGD","LU1061106388.HKD","LU0289739699.SGD","LU1571399168.USD","LU1917777945.USD","LU1116320901.HKD","LU0965509010.AUD","SG9999013999.USD","LU2461242641.AUD","LU0942090050.USD","LU1069347547.HKD","LU0266013472.USD","SG9999014559.SGD","SG9999001176.SGD","BK0196","LU1035773651.USD","SG9999015358.SGD","IE00BBT3K403.USD","SG9999014575.USD","LU0238689110.USD","SGXZ57979304.SGD","LU2361044865.SGD","BK4007","LU0070302665.USD","LU0985320562.USD","LU0130517989.USD","LU1066051498.USD","LU2106854487.HKD","LU2468319806.SGD","LU1057294990.SGD","LU0965509283.SGD","LU1585245621.USD","LU2125154935.USD","LU2324357040.USD","BK0046","LU0265550946.USD","IE00B1BXHZ80.USD","BK4533","LU0965508806.USD","LU2112291526.USD","LU1116320737.USD","IE0002141913.USD","LU1989771016.USD","LU1934455277.USD","SG9999014542.SGD","LU2089984988.USD","LU1291159041.SGD","SG9999002224.SGD","BK4550","LU1162221912.USD","LU1934455194.USD","LU1064131003.USD","LU1941712264.USD","LU1699723380.USD","LU1064130708.USD","LU1941712348.USD","LU0477156953.USD","LU1983299246.USD","LU0320765646.SGD","LU0648001328.SGD","LU2023250504.SGD","LU2125154778.USD","LU2580892862.HKD","BK0077","IE00BJT1NW94.SGD","LU1066053197.SGD","IE000M9KFDE8.USD","LU0980610538.SGD","LU1328615791.USD","SG9999015341.SGD","SG9999014567.USD","LU0234572021.USD","LU0861579265.USD","LU0211331839.USD","LU1093756168.USD","BK4559","LU0868494617.USD","LU1066051225.USD","IE0009355771.USD","LU2361045086.USD","BK4534","LU0203345920.USD","LU2023250843.SGD","BK0239","LU0432979614.USD","LU1989772923.USD","LU0122379950.USD","BK4516","LU0203347892.USD","LU1929549753.HKD","LU2148510915.USD","LU0265550359.USD","LU1974910355.USD","LU1037948541.HKD","LU0098860793.USD","LU1201861249.SGD","IE00BLSP4452.SGD","LU0106261372.USD","LU0006306889.USD","LU1023059063.AUD","LU2580892789.USD","SG9999001176.USD","300122","IE00BSNM7G36.USD","IE00BJJMRZ35.SGD","LU0320765489.SGD","LU1934455863.HKD","LU2361044949.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624668214","title":"智飞生物（300122）披露与默沙东调整战略合作协议，4月3日股价下跌2.23%","url":"https://stock-news.laohu8.com/highlight/detail?id=2624668214","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2624668214?lang=zh_cn&edition=full","pubTime":"2026-04-03 22:07","pubTimestamp":1775225235,"startTime":"0","endTime":"0","summary":"截至2026年4月3日收盘，智飞生物报收于15.33元，较前一交易日下跌2.23%，最新总市值为366.97亿元。公司于近日披露《关于与默沙东调整战略合作协议的公告》。公告显示，重庆智飞生物制品股份有限公司与默沙东于2026年4月2日签署《经修订和重述的供应、经销与共同推广协议》，取代双方2023年1月21日签署的原协议。默沙东将向智飞生物供应九价HPV疫苗、五价轮状病毒疫苗、23价肺炎疫苗，智飞生物在中国大陆地区独家进口、经销和共同推广上述产品。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026040300043206.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU2580892789.USD","LU1328615791.USD","LU2148510915.USD","BK0196","BK0046","LU1064131003.USD","BK0188","300122","BK0239","LU1064130708.USD","BK0077","LU2580892862.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624047555","title":"智飞生物修订与默沙东协议 “五连板”津药药业称无在研创新药","url":"https://stock-news.laohu8.com/highlight/detail?id=2624047555","media":"财闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2624047555?lang=zh_cn&edition=full","pubTime":"2026-04-02 21:20","pubTimestamp":1775136000,"startTime":"0","endTime":"0","summary":"默沙东授权公司按照协议约定，独家在中国大陆地区以默沙东商标进口、共同推广、经销和销售协议产品的权利。新协议不再约定协议产品的基础采购金额，公司与默沙东将根据市场预期需求和实际接种情况，协商确认预期采购与供应计划，公司据此滚动采购协议产品。本协议的签署深化了公司与默沙东的战略伙伴关系，有利于增强双方对市场变化的协同应对能力，减轻公司的经营压力并降低风险。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2026-04-02/doc-inhtcnfs0882895.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["LU1037948897.HKD","LU0006306889.USD","LU0648001328.SGD","IE00B1BXHZ80.USD","LU1066051811.HKD","LU2112291526.USD","LU0868494617.USD","LU1162221912.USD","BK0012","BK1161","LU1093756325.SGD","LU2361045086.USD","LU1037948541.HKD","LU2023250504.SGD","LU1571399168.USD","IE00BN8TJ469.HKD","SG9999002224.SGD","IE00BJJMRZ35.SGD","LU1093756168.USD","LU1066053197.SGD","LU1201861249.SGD","IE00BLSP4239.USD","BK0102","LU2468319806.SGD","SG9999015341.SGD","LU2148510915.USD","IE0009355771.USD","LU0130102774.USD","LU0477156953.USD","SG9999014542.SGD","LU1917777945.USD","LU0265550946.USD","LU1699723380.USD","LU1934455863.HKD","BK4516","LU1941712264.USD","LU1941712348.USD","BK0046","LU2461242641.AUD","LU1989772840.SGD","LU2360032135.SGD","LU0098860793.USD","LU1929549753.HKD","SG9999001176.SGD","LU2580892862.HKD","SG9999001176.USD","BK4533","IE00BJT1NW94.SGD","BK1574","LU0211331839.USD","LU0203347892.USD","LU0965509283.SGD","IE0002141913.USD","IE00BBT3K403.USD","LU1064130708.USD","LU1430594728.SGD","LU0106261372.USD","LU1585245621.USD","IE000M9KFDE8.USD","LU0265550359.USD","LU0238689110.USD","LU1974910355.USD","LU2361044865.SGD","SGXZ57979304.SGD","LU0289739699.SGD","LU1291159041.SGD","LU0234572021.USD","LU0861579265.USD","600488","LU0868494708.USD","LU0965509010.AUD","BK4585","LU0058720904.USD","LU0942090050.USD","LU2125154778.USD","IE00BSNM7G36.USD","LU2106854487.HKD","LU2361044949.HKD","SG9999002232.USD","LU2023250843.SGD","SG9999014559.SGD","BK4550","BK0028","LU0965508806.USD","LU1983299246.USD","BK4007","LU0965509101.SGD","LU0980610538.SGD","LU0320765489.SGD","LU1069347547.HKD","BK0188","LU1116320737.USD","LU1035773651.USD","LU1328615791.USD","LU0320765646.SGD","LU0130517989.USD","LU1989771016.USD","BK0196","SG9999014575.USD","BK0077","SG9999013999.USD","LU1023059063.AUD","LU2125154935.USD","LU1061106388.HKD","LU0122379950.USD","LU0203345920.USD","300122","SG9999015358.SGD","LU2324357040.USD","BK4559","LU2089984988.USD","LU0070302665.USD","LU1066051498.USD","SG9999014567.USD","BK4534","LU1057294990.SGD","LU2580892789.USD","LU1116320901.HKD","LU1064131003.USD","LU1989772923.USD","BK4588","IE00BFTCPJ56.SGD","LU0208291251.USD","SG9999001440.SGD","LU0985320562.USD","LU0432979614.USD","BK0239","IE00B4R5TH58.HKD","LU1934455194.USD","LU1934455277.USD","IE00B2B36J28.USD","IE00BLSP4452.SGD","LU0266013472.USD","LU1066051225.USD"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1779597777277,"stockEarnings":[{"period":"1week","weight":-0.0652},{"period":"1month","weight":-0.0798},{"period":"3month","weight":-0.168},{"period":"6month","weight":-0.3036},{"period":"1year","weight":-0.2808},{"period":"ytd","weight":-0.2549}],"compareEarnings":[{"period":"1week","weight":-0.0054},{"period":"1month","weight":0.0016},{"period":"3month","weight":0.0076},{"period":"6month","weight":0.0725},{"period":"1year","weight":0.2168},{"period":"ytd","weight":0.0363}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"重庆智飞生物制品股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"119480人(较上一季度减少1.83%)","perCapita":"11837股","listingDate":"2010-09-28","address":"重庆市两江新区庆云路1号50层","registeredCapital":"239378万元","survey":" 重庆智飞生物制品股份有限公司的主营业务是疫苗、生物制品研发、生产、销售、推广、配送及进出口。公司的主要产品是盟威克、盟纳康、喜菲贝、盟纳克、智克威得、宜卡、微卡、优威克、四价流感病毒裂解疫苗、佳达修、佳达修9、乐儿德、纽莫法、维康特、欣安立适。","listedPrice":37.98},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"智飞生物(300122)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供智飞生物(300122)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"智飞生物,300122,智飞生物股票,智飞生物股票老虎,智飞生物股票老虎国际,智飞生物行情,智飞生物股票行情,智飞生物股价,智飞生物股市,智飞生物股票价格,智飞生物股票交易,智飞生物股票购买,智飞生物股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"智飞生物(300122)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供智飞生物(300122)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}